Skip to content

INC

Incanthera plc

Access


ISIN

GB00BGL7YW15

Bid

6.40

Mid

6.55

Ask

6.70

Key Information

Price Change
0.00%
Year High
6.95
Year Low
6.55
Last Trade
17 May 23
Market Cap
£5.07M
Par
0.02
Bid
6.40
Mid Price
6.55
Ask
6.70
Instrument Type
Ordinary Shares
MIFID Status
MTF
Tradable Securities
77.46M
Sector
Healthcare

Prices in GBX except for Market Cap in GBP

About Incanthera plc

The Company is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions. The Company’s current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and is currently being prepared for licensing to a commercial partner within 12-18 months. The Company originated from the Institute of Cancer Therapeutics – University of Bradford and, in addition to Sol, has acquired and developed a portfolio of specific cancer-targeting therapeutics through a pipeline agreement with the Institute of Cancer Therapeutics and other corporate acquisitions. Incanthera’s strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.<p>

Incanthera plcAccess

Latest Trades

DateVolumePrice (GBX)Value (GBP)

17 May 23

09:12

7696.4049.22

21 Apr 23

09:28

33,3006.502,164.50

21 Apr 23

09:28

33,3006.402,131.20

27 Mar 23

12:06

2106.4013.44

22 Mar 23

10:19

6,0006.40384.00
View all trades

Latest Announcements

DateTitle

05 Apr 23

12:04

Incanthera PLC - Result of Warrant Holder Meeting

30 Mar 23

07:00

Incanthera PLC - Further re: Director's Dealing

13 Mar 23

07:00

Incanthera PLC - Director’s Dealing and Proposed Warrant Extension

07 Dec 22

07:00

Incanthera PLC - Half-year Report

27 Sep 22

12:58

Incanthera PLC - Result of AGM
View all announcements

Financial Information

Download a glossary of terms  

All data provided by Fregnan Data

GBPLatest Results 2021-03-31
EnterpriseValue£11
EV / EBITDA-11.15
EV / EBIT-11.15
PE Ratio-12.52
PE Ratio Growth158.54%
Dividend Yield0
Free Cash Yield-6.88%

Address

Registered Address

76 King Street, Manchester, M2 4NH, United Kingdom

Email

suzanne.brocks@incanthera.com

Phone

+44 (0) 161 817 5005

Contacts

Corporate Adviser

Cairn Financial Advisers LLP., 9th Floor, 107 Cheapside, London, EC2V 6DN, United Kingdom

Registrar

Neville Registrars Limited , Neville House,Steelpark Road, Halesowen, West Midlands, B62 8HD, United Kingdom
Loading...

Company

  • About
  • News
  • Investor Relations
  • Contact
  • Careers

© Aquis Exchange 2023. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal